This 2025 study gave AKBA, the lead boswellic acid, by mouth to rats with chemically induced knee damage. Compared with untreated rats, AKBA suppressed MMP13, raised TIMP-1 (an MMP brake) and SOX9 (a cartilage-building switch), lowered the collagen breakdown marker CTX-II, and turned down inflammatory signalling through NF-kB.
Male Wistar rats were split into three groups of nine: sham, joint damage only, and joint damage plus AKBA. Joint damage was caused by injecting 3 mg of monosodium iodoacetate into the right knee on day 0. AKBA was given by mouth daily from day 3 to day 14. The researchers measured knee swelling, scored cartilage under the microscope, and measured enzymes, inflammatory signals, antioxidant pathways and cell death markers.
AKBA brought knee swelling back to near normal and normalised the cartilage damage scores (modified Mankin and OARSI). It suppressed MMP13, raised TIMP-1 and SOX9, and lowered serum CTX-II, a fragment of broken type II collagen. It substantially lowered HMGB1, TLR4, NF-kB and TNF-alpha, raised the antioxidant regulators Nrf2 and HO-1, curbed markers of necroptosis (a form of programmed cell death), and lowered two microRNAs, miR-34a-5p and miR-146a.
This was 27 rats over two weeks, with damage caused by a chemical injection, which differs from how cartilage changes in people. The treated group is labelled AKBA250, but the abstract does not state the dose unit, so the dose cannot be read from the abstract. Pure AKBA is not the same as a boswellia extract, and rat results do not carry over to people.
Many boswellia studies report MMP-3 or MMPs as a group. This one names MMP13 and found AKBA suppressed it in living animals, alongside a rise in TIMP-1, one of the body's own brakes on MMPs, and a fall in a type II collagen breakdown marker.
In animal and lab studies, yes. AKBA, the lead boswellic acid, suppressed MMP13 in rats with chemically induced knee damage, and a frankincense extract lowered MMP13...
In two main ways. Cells release MMP13 as an inactive proenzyme that must be cut before it works, and the body makes its own inhibitors, the TIMPs. TIMP-1, TIMP-2 and...
Yes, in lab studies. The inflammatory messenger IL-1 raised MMP13 in human cartilage and cartilage cells in several studies, and TNF-alpha did too. To switch the MMP13...